Deep Track Capital LP Has $5.71 Million Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Deep Track Capital LP increased its stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 72.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,119,162 shares of the biopharmaceutical company's stock after acquiring an additional 1,314,796 shares during the period. Deep Track Capital LP owned approximately 11.95% of Inovio Pharmaceuticals worth $5,708,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Alpine Global Management LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $31,000. Bank of Montreal Can bought a new stake in Inovio Pharmaceuticals during the 4th quarter valued at approximately $43,000. Boothbay Fund Management LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at approximately $44,000. Barclays PLC lifted its holdings in shares of Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 5,111 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Inovio Pharmaceuticals by 118.2% in the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock worth $73,000 after acquiring an additional 21,512 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on INO shares. HC Wainwright reissued a "neutral" rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. Royal Bank of Canada dropped their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating for the company in a research report on Wednesday, March 19th. Finally, StockNews.com cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $12.20.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock traded up $0.14 during midday trading on Monday, reaching $1.94. The stock had a trading volume of 414,456 shares, compared to its average volume of 588,650. The stock has a market capitalization of $70.96 million, a P/E ratio of -0.48 and a beta of 1.40. The firm's fifty day simple moving average is $1.80 and its 200-day simple moving average is $2.59. Inovio Pharmaceuticals, Inc. has a 1-year low of $1.42 and a 1-year high of $13.44.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million. On average, sell-side analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.